[8-K] ZyVersa Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

ZyVersa Therapeutics announced a leadership change. On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs. Dr. Guzman joined the company in January 2015 after more than 35 years practicing interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. The company states he resigned to spend more time with his family and to travel.

Insights

Healthcare governance analyst

Leadership change disclosed; routine governance update.

ZyVersa Therapeutics reports the resignation of its Chief Medical Officer, Pablo Guzman, M.D., effective October 10, 2025. The company attributes the departure to personal reasons, namely family and travel.

Such changes can shift clinical leadership responsibilities, but the excerpt does not detail successor plans or program impacts. Without those specifics, the filing functions as a governance disclosure rather than an operational update.

Subsequent filings may provide role coverage or transition details if applicable.

false 0001859007 0001859007 2025-10-10 2025-10-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2025

ZYVERSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41184		86-2685744
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2200 N. Commerce Parkway, Suite 208, Weston, Florida		33326
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (754) 231-1688

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ZVSA		—(1)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(1) The Company’s common stock is quoted on the OTCQB® Venture Market under the symbol “ZVSA.”

Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs of ZyVersa Therapeutics, Inc. (the “Company”). Dr. Guzman first joined the Company in January 2015, following more than 35 years of practicing medicine/interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. Dr. Guzman resigned to spend more time with his family and to travel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 15, 2025	ZYVERSA THERAPEUTICS, INC.
	/s/ Stephen Glover
	Stephen Glover
	Chief Executive Officer

FAQ

What did ZyVersa Therapeutics (ZVSA) announce?

The company announced that Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs effective October 10, 2025.

Who is the ZyVersa (ZVSA) executive who resigned?

Pablo Guzman, M.D., who served as Chief Medical Officer and Senior Vice President of Medical Affairs.

When was the ZyVersa CMO resignation effective?

October 10, 2025.

What reason was given for the ZyVersa CMO’s resignation?

He resigned to spend more time with his family and to travel.

How long had Dr. Pablo Guzman been with ZyVersa (ZVSA)?

He joined the company in January 2015.

What was Dr. Guzman’s background before ZyVersa?

Over 35 years practicing medicine/interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale.